Table 2.
Review of Recent Studies on Prognostic Factors in Patients With SCCE.
| Author | Year | Sample size | Median age (years) | MST (month) | 5-year OS (%) | Prognostic factors |
|---|---|---|---|---|---|---|
| Our study | 2020 | 162 | 65-69 | 11 | 8.0 | Age, T staging, tumor size, primary site, and chemotherapy |
| Xiao Q et al19 | 2019 | 137 | 59.3 | 12 | 11.9 | VALSG stage, N stage, and multimodal treatment |
| Chen BQ et al12 | 2019 | 42 | 55 | 12.9 | 13.9 | ECOG PS, lesion length, chemotherapy, and dose of RT |
| Jeene PM et al15 | 2019 | 58 | 55 | 16 | N/A | Chemotherapy cycles |
| Xu L et al13 | 2017 | 152 | 61 | 28 | 8.2 | Treatment modality and N stage |
| Song YQ et al14 | 2015 | 352 | N/A | 8 | N/A | Stage, age, year, and RT |
| Gao R et al18 | 2014 | 225 | 59.5 | 19 (LD) 9 (ED) |
N/A | Chemotherapy |
| Meng MB et al16 | 2013 | 127 | N/A | 21.0 | N/A | Tumor location and type of treatment |
| Ding J et al6 | 2013 | 106 | 58 | N/A | N/A | Chemotherapy |
| Kukar M et al17 | 2013 | 387 | 68 | N/A | N/A | Age, gender, race, and stage |
| Chen SB et al10 | 2011 | 40 | 57 | 13.0 | 10.5 | Operation and chemotherapy |
ECOG: Eastern Cooperative Oncology Group; ED: extensive disease; F: female; LD: limited disease; N/A: Not available; M: male; PS: performance status; RT: radiotherapy; SCCE: small cell carcinoma of the esophagus; VALSG: Veterans’ Administration Lung Study Group.